Stephanie Saw, Medical Oncologist at National Cancer Center of Singapore, reshared a post by Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, on X, adding:

“Delighted to share our review paper on ADCs in NSCLC with AGA is out!

Very timely given the anticipated data readouts this year.

Such an honour to be a part of this awesome team, special thanks to Giannis Mountzios and Jordi Remon for leading this.”

Quoting Giannis Mountzios‘s post:

“Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted NSCLC

Just out in ESMO Cancer Treatment Reviews a comprehensive overview on current landscape, challenges and perspectives.

Grateful to work with a global amazing team, including Stephanie Saw, Lizza Hendriks, Jessica Menis, Tina Cascone, Oscar Arrieta, Jarushka Naidoo, Alfredo Addeo, Solange Peters and senior author Jordi Remon.”

Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target

Authors: Giannis Mountzios, et al.

Stephanie Saw: Our review paper on ADCs in NSCLC with AGA is out